Molecular malignancy in melanocytic lesions
Disclosed are methods for determining whether a melanocyte-containing sample (such as a nevus or other pigmented lesion) is benign or a primary melanoma. These methods can include detecting (at the molecular level, e.g., mRNA, miRNA, or protein) the expression of at least two disclosed genes in a biological sample obtained from a subject. Also provided are arrays and kits that can be used with the methods.
HTG Molecular Diagnostics, Inc. (Tucson, AZ); John Wayne Cancer Institute (Santa Monica, CA)
Wang, Hui; Roberts, Christopher; Maddula, Krishna; Lu, Zhenquiang; Vasicek, Tom; Kerns, BJ; Seligmann, Bruce E.; and Hoon, Dave S B, "Molecular malignancy in melanocytic lesions" (2013). Technology Transfer - Patents. 20.